Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer

Metastatic colorectal cancer (mCRC) predominantly contributes to cancer-related mortalities secondary to distant metastasis. This study aimed at investigating anti-tumor activity and safety of mebendazole in patients with mCRC. This prospective, randomized double blind placebo-controlled study enrol...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Life sciences (1973) 2022-06, Vol.299, p.120536-120536, Article 120536
Hauptverfasser:	Hegazy, Sahar K., El-Azab, Gamal A., Zakaria, Fatma, Mostafa, Mohamed F., El-Ghoneimy, Reham A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized Anticancer properties Antigens Antineoplastic Combined Chemotherapy Protocols Antiparasitic agents Antitumor agents Bevacizumab Bevacizumab - pharmacology Bevacizumab - therapeutic use Cancer Carcinoembryonic Antigen Chemotherapy Colonic Neoplasms - drug therapy Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - pathology Computed tomography Drug Repositioning Fluorouracil FOLFOX4 & bevacizumab Growth factors Humans Mebendazole Mebendazole - pharmacology Mebendazole - therapeutic use Metastases Metastatic colorectal cancer Patients Placebos Progression free survival Prospective Studies Retrospective Studies Safety Serum levels Statistical analysis Survival Tumors Vascular endothelial growth factor Vascular Endothelial Growth Factor A
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!